Form 4: Edwards Lifesciences CEO Bernard J. Zovighian Reports Stock and Option Grants

CEO Bernard J. Zovighian reports the acquisition of restricted stock units and stock options, along with a disposition of shares to cover tax obligations.

Summary

• On May 7, 2024, Bernard J. Zovighian, CEO of Edwards Lifesciences, reported transactions involving the company's stock.
• Zovighian acquired 33,500 shares of common stock through restricted stock units granted under the company's Long-Term Stock Incentive Compensation Program.
• These restricted stock units will vest in four equal annual installments starting one year after the grant date.
• Additionally, Zovighian acquired options to purchase 178,400 shares of common stock, also vesting in four equal annual installments beginning one year after the grant date.
• Zovighian also disposed of 647 shares of common stock to satisfy tax obligations at a price of $85.09 per share.
• Following these transactions, Zovighian directly owns 79,688.9005 shares of common stock and indirectly owns 3,267.6552 shares through a 401(k).
• He also directly holds options for 178,400 shares and performance rights for 33,500 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grants of stock and options are a positive sign of alignment between management and shareholders, while the sale of shares for tax purposes is a neutral event.

Positives

• The grant of restricted stock units and stock options aligns the CEO's interests with those of the shareholders, incentivizing long-term performance.
• The vesting schedule of the grants encourages continued service and commitment from the CEO.

Negatives

• The disposal of 647 shares, while for tax obligations, represents a small reduction in the CEO's direct holdings.

Risks

• The actual number of restricted stock units that vest could range from 0% to 175% of the target award, depending on the achievement of certain performance goals over a three-year period, introducing uncertainty.

Future Outlook

The restricted stock units and stock options are part of the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program, suggesting a continued focus on aligning executive compensation with long-term company performance.

Industry Context

Executive compensation through stock grants and options is a common practice in the medical device industry to incentivize performance and align management interests with shareholder value. This filing reflects standard compensation practices for a CEO in a publicly traded company.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are standard practice for executive compensation in the medical device industry, similar to companies like Medtronic, Stryker, and Boston Scientific.
• The vesting schedules (four equal annual installments) are also typical for these types of grants.
• Performance-based vesting, as mentioned for the restricted stock units, is increasingly common to tie executive compensation to specific company goals, aligning with practices seen at other major medical device firms.

Stakeholder Impact

• Shareholders may view the stock and option grants as a positive sign, aligning management's interests with long-term company performance.
• Employees may see the grants as part of a broader compensation strategy that rewards performance and contributes to the company's success.

Key Dates